Dow Jones

38,686.32

1.51%

Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

Regístrate

VERV

Verve Therapeutics (VERV)

Verve Therapeutics Inc

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:VERV

1 2 3 4 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
31/05/2024	15:01	GlobeNewswire Inc.	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:VERV	Verve Therapeutics Inc
31/05/2024	06:14	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VERV	Verve Therapeutics Inc
31/05/2024	06:00	GlobeNewswire Inc.	Verve Therapeutics Announces Leadership Update	NASDAQ:VERV	Verve Therapeutics Inc
30/05/2024	15:01	GlobeNewswire Inc.	Verve Therapeutics to Participate in Upcoming Investor Conferences	NASDAQ:VERV	Verve Therapeutics Inc
08/05/2024	06:30	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:VERV	Verve Therapeutics Inc
08/05/2024	06:00	GlobeNewswire Inc.	Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results	NASDAQ:VERV	Verve Therapeutics Inc
07/05/2024	06:00	GlobeNewswire Inc.	Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102	NASDAQ:VERV	Verve Therapeutics Inc
02/04/2024	06:00	GlobeNewswire Inc.	Verve Therapeutics Announces Updates on its PCSK9 Program	NASDAQ:VERV	Verve Therapeutics Inc
27/02/2024	07:32	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:VERV	Verve Therapeutics Inc
27/02/2024	07:00	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:VERV	Verve Therapeutics Inc
27/02/2024	06:30	GlobeNewswire Inc.	Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results	NASDAQ:VERV	Verve Therapeutics Inc
16/02/2024	15:30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:VERV	Verve Therapeutics Inc
01/02/2024	05:30	GlobeNewswire Inc.	Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	NASDAQ:VERV	Verve Therapeutics Inc
02/01/2024	05:30	GlobeNewswire Inc.	Verve Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference	NASDAQ:VERV	Verve Therapeutics Inc
01/12/2023	15:00	GlobeNewswire Inc.	Verve Therapeutics Announces Closing of Public Offering of Common Stock, Full Exercise by Underwriters of Option to Purchase Additional Shares and Closing of Concurrent Private Placement	NASDAQ:VERV	Verve Therapeutics Inc
29/11/2023	15:47	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:VERV	Verve Therapeutics Inc
29/11/2023	05:47	Dow Jones News	Verve Therapeutics Shares Tumble Premarket After Stock Sales	NASDAQ:VERV	Verve Therapeutics Inc
28/11/2023	21:37	GlobeNewswire Inc.	Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement	NASDAQ:VERV	Verve Therapeutics Inc
28/11/2023	15:01	GlobeNewswire Inc.	Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private Placement	NASDAQ:VERV	Verve Therapeutics Inc
12/11/2023	14:30	GlobeNewswire Inc.	Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial Hypercholesterolemia	NASDAQ:VERV	Verve Therapeutics Inc
07/11/2023	05:30	GlobeNewswire Inc.	Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results	NASDAQ:VERV	Verve Therapeutics Inc
31/10/2023	05:59	Dow Jones News	Beam Therapeutics to Sell Rights in Verve Licensing Deal to Lilly for $250 Million Upfront	NASDAQ:VERV	Verve Therapeutics Inc
31/10/2023	05:01	GlobeNewswire Inc.	Verve and Lilly Relationship Expands to Include Verve’s In Vivo Gene Editing Programs Targeting PCSK9 and ANGPTL3	NASDAQ:VERV	Verve Therapeutics Inc
23/10/2023	06:22	Dow Jones News	Verve Therapeutics Gets Clinical Hold For VERVE-101 Lifted By FDA	NASDAQ:VERV	Verve Therapeutics Inc
23/10/2023	05:30	GlobeNewswire Inc.	Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia	NASDAQ:VERV	Verve Therapeutics Inc
26/09/2023	05:30	GlobeNewswire Inc.	Verve to Present Interim Data from the heart-1 Phase 1b Clinical Trial of VERVE-101 in HeFH Patients at the American Heart Association’s Scientific Sessions 2023	NASDAQ:VERV	Verve Therapeutics Inc
21/09/2023	15:05	GlobeNewswire Inc.	Verve Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference	NASDAQ:VERV	Verve Therapeutics Inc
18/09/2023	05:30	GlobeNewswire Inc.	Verve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D., as Chief Medical Officer	NASDAQ:VERV	Verve Therapeutics Inc
10/08/2023	05:30	GlobeNewswire Inc.	Verve Therapeutics Highlights Recent Company Progress and Reports Second Quarter 2023 Financial Results	NASDAQ:VERV	Verve Therapeutics Inc
03/08/2023	05:30	GlobeNewswire Inc.	Verve Therapeutics to Present at the Canaccord 43rd Annual Growth Conference	NASDAQ:VERV	Verve Therapeutics Inc